Pre-Made Detumomab biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting human?B-cell lymphoma is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma.
Detumomab is comprised of an anti-B-cell lymphomas monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage.